

Special Issue

Circulating Pro- and Anti-angiogenic Factors in Cardiovascular Disorders

Message from the Guest Editor

Angiogenesis is a process strictly regulated and modulated by the microenvironment and multiple pro- and antiangiogenic factors. Proper angiogenesis is the result of the balance between factors inducing and inhibiting it. The disturbance in this equipoise may lead to life-threatening vascular-related diseases influencing patients' life quality. An increasingly better understanding of angiogenesis and the factors affecting this process leads to the development of new, personalized therapies focused on ischemic diseases as well as those related to overintense angiogenesis, such as rheumatoid arthritis, psoriasis or neoplasms. In the last decade, therapeutic angiogenesis is gathering more and more scientific attention in the field of ischemic tissue treatment due to the stimulation of new vascular vessel creation based on existing vascular systems. In this Special Issue, *in vitro* and *in vivo* studies, original research and reviews are all welcome.

Guest Editor

Dr. Paweł Maga

Department of Angiology, Faculty of Medicine, Jagiellonian University Medical College, Krakow, Poland

Deadline for manuscript submissions

closed (30 September 2023)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 5.2
Indexed in PubMed



mdpi.com/si/169219

Biomedicines
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 5.2
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA

2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q2 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 15.3 days after submission; acceptance to publication is undertaken in 3.4 days (median values for papers published in this journal in the first half of 2024).